BIIB logo Biogen : BIIB

BIIB

Stock Data

$187.06

Change down

$2.22 (1.17%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Biogen Inc. is a pioneer in the biotechnology sector, focusing on developing treatments for neurological and neurodegenerative conditions. With a global presence, Biogen offers a range of therapies for diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. Its portfolio includes well-known drugs like TECFIDERA, SPINRAZA, and ADUHELM. Additionally, Biogen is involved in creating biosimilars, which are essentially generic versions of biologic drugs, expanding its impact on healthcare. Founded in 1978 and based in Cambridge, Massachusetts, Biogen continues to push the boundaries of medicine through innovation and partnerships.

All Biogen Articles

606 Articles

1 2 3 41

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.